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INTRODUCTION
Arterial hypertension (AH) is one of the most 
socially significant diseases. It is largely related to 
morbidity, disability and mortality of the popula-
tion. The incidence of hypertension varies between 
4.8 and 30.3% in different countries and geograph-
ical areas. In the large epidemiological study PURE 
(Prospective Urban Rural Epidemiology), conduct-
ed in 17 countries on five continents, the incidence 
of hypertension is 40.7% and only 13.1% of patients 
were with controlled hypertension (1). In our coun-
try 15% of the population over 18 years of age suffers 
from hypertension. The disease affects both sexes 
and the percentage of hypertensive patients increas-
es with age.
The aims of modern antihypertensive therapy 
are not only limited to reduction and normalization 
of blood pressure (BP), but also have to lower the car-
diovascular risk of patients (2). All hypertensive pa-
tients, including those on medical treatment, should 
make changes in their lifestyle designed to control 
risk factors and in order to reduce the doses of anti-
hypertensive drugs. Changes in lifestyle, which help 
to decrease blood pressure and total cardiovascu-
lar risk, are smoking cessation, reducing and main-
taining a healthy weight, reducing alcohol and sodi-
um chloride intake, increased physical activity, in-
creased intake of fruits and vegetables, decreased in-
take of saturated and total fat (3). The latest guide-
lines for management of arterial hypertension (2, 4, 
5) recommend initiation of antihypertensive therapy 
for patients with systolic blood pressure ≥ 140 mm 
Hg or diastolic blood pressure≥ 90 mm Hg. The po-
sitions on the time of initiation of antihypertensive 
drug therapy are similar: AH II degree (5) or AH II 
or III degree (2), treatment should begin immedi-
ately, while AH I degree can wait to assess the effect 
of non-pharmacologic methods. Pharmacological 
therapy is recommended for patients with AH I de-
gree when there is organ damage as in type 2 diabe-
tes, cardiovascular disease or chronic kidney disease 
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(2). According to the management of Joint Nation-
al Committee (JNC) 8 Hypertension Guidelines (4) 
the initial antihypertensive therapy should include 
a thiazide-type diuretic, a calcium channel blocker 
(CCB), an angiotensin-converting enzyme inhibitor 
(ACEI) or an angiotensin receptor blocker (ARB), as 
each of those class drugs have comparable positive 
effects on overall mortality, cardiovascular, cerebro-
vascular and renal adverse events, with the exception 
of heart failure, wherein the thiazide-type diuretics 
have more pronounced prophylactic efficacy. JNC 8 
does not recommend a beta-blocker as an initial se-
lection of antihypertensive therapy, as well as alpha-
blockers, mixed alpha
1
/beta-blockers (e.g. carvedilol), 
vasodilating beta-blockers (e.g. nebivolol), central al-
pha
2
-adrenergic agonists (e.g. clonidine), direct vaso-
dilators (e.g. hydralazine), aldosterone receptor an-
tagonists (e.g. spironolactone), peripherally acting 
adrenergic antagonist (e.g. reserpine) and loop di-
uretics (e.g. furosemide). European Society of Hyper-
tension (ESH) and European Society of Cardiology 
(ESC) added to the major classes of antihypertensive 
drugs beta blockers and points out that they are all 
suitable for initiating and maintaining antihyperten-
sive therapy, as monotherapy or combined with each 
other. One of the main advantages of five antihyper-
tensive classes is their ability to lower blood pressure 
by different mechanisms. Therefore, they can be ef-
fectively combined with each other and their antihy-
pertensive effect is additive. The only exception is the 
combination of two blockers of the renin-angioten-
sin-aldosterone system (RAAS), which is associated 
with increased incidence of renal side effects and hy-
perkalemia. Therefore, this combination is not rec-
ommended (6). Priority should be given to drugs that 
are administered once daily and have a long-lasting 
effect (≥24 hours). Monotherapy achieves target lev-
els of BP in a small number of patients and therefor-
ethe most of them require combination therapy. Ini-
tial treatment usually is a monotherapy or a combi-
nation of two drugs at low doses, with a consequent 
increase in the number of doses and drugs, if nec-
essary. Fixed dose combinations of two drugs can 
bring additional benefits with the easy regimen. De-
spite that the “first-line agents” lately are not applied, 
most guidelines recommend initiation of antihyper-
tensive therapy with RAAS blocker or calcium chan-
nel blocker, indicating that the initial choice should 
comply with accompanying diseases. Finally, JNC 8 
emphasizesthe need for the clinician to motivate pa-
tients to be compliant and adhere to their medica-
tion regimen.
Pharmacologic treatment of hypertension re-
lies heavily on the above five major antihypertensive 
drug classes, each with its advantages and disadvan-
tages. Each class of antihypertensive medication has 
specific advantages and contraindications in specif-
ic clinical situations. The choice of a particular drug 
is individual for each patient, taking into account the 
accompanying diseases (7) (table 1).
Condition Drug of choice
Hypertension in patients with diabetes mellitus ACEIs, ARBs, CCBs
Hypertension in patients with peripheral vascular 
disease
CCBs
Hypertension in patients with angina pectoris Beta blockers or CCBs
Hypertension in patients with renal impairment/
microalbuminuria
ACEIs or ARBs
Hypertension in patients with end stage renal disease/
albuminuria
ACEIs or ARBs (dialysis patients), loop diuretics
Hypertension in patients with heart failure
ACEIs or ARBs, beta-blockers (carvedilol, nebivo-
lol, metoprolol, bisoprolol), diuretics, aldosterone 
antagonists
Hypertension in older patients Diuretics or CCBs
Table 1. Preferred antihypertensive drugs for specific conditions
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Diuretics
Diuretics are one of the major classes of antihy-
pertensive medication and are among the most pre-
scribed ones. Their antihypertensive effect is a result 
of reduced plasma volume and peripheral vasodilata-
tion. Recently diuretics are rarely used as monother-
apy, but are usually part of combination therapy with 
RAAS blockers. Different classes of diuretics, repre-
sentatives of various groups and the most common 
side effects are listed in Table 2.
Frequency of ADRs of thiazide and thiazide-
like diuretics decreases in dose reduction manner 
and in combination with ACE – inhibitors. Hypo-
kalemia increases the toxicity of cardiac glycosides. 
Ototoxicity of furosemide is increased when co-ad-
ministered with aminoglycosides, carboplatin, cis-
platin and paclitaxel. It may cause photosensitivity. 
There is a danger for both groups (thiazide and loop 
diuretics) of cross-allergy reactions to sulfonamides. 
In renal insufficiency can be used indapamide or fu-
rosemide. Amiloride and triamterene, due to weak 
antihypertensive effect are used in combined diuret-
ic preparations for retention of potassium.
In clinical practice, the most often prescribed 
diuretic is hydrochlorothiazide (HCTZ). It is also the 
major component of the combined antihypertensive 
drugs. However, it is less effective in the reduction 
of systolic blood pressure and the risk of cardiovas-
cular events is higher compared to chlorthalidone. 
Greater effectiveness of chlorthalidone than HCTZ is 
strongly suggested by post hoc analysis of the MRFIT 
(Multiple Risk Factor Intervention Trial) data, which 
showed better outcomes with chlorthalidone (6).
ACE inhibitors (ACEIs)
They are established and effective drugs for 
the treatment of hypertension, by lowering periph-
eral vascular resistance due to decreased production 
of angiotensin II. In plasma, synthesized in the kid-
ney renin, cleaves four amino acids from circulating 
angiotensinogen, which is synthesized in the liver, to 
form the biologically inactive decapeptide angioten-
sin I. Angiotensin-converting enzyme (ACE) cleaves 
two amino acidsfrom angiotensin I to form the bio-
logically active octapeptide (1-8) angiotensin II. An-
giotensin II exerts its effects by binding to two G pro-
tein–coupled receptors, the angiotensin type 1 (AT
1
) 
and angiotensin type 2 (AT
2
) receptors. The predom-
inant angiotensin receptor in the vasculature is the 
AT
1
 receptor. Activation of the AT
1
 receptor leads to 
vasoconstriction, cell growth, aldosterone secretion, 
and catecholamine release, whereas activation of the 
AT
2
 receptor leads to vasodilation, inhibition of cell 
growth, natriuresis, and bradykinin release. Inhibi-
tion of ACE enzyme leads to decreased production 
of angiotensin II, which is the reason of reduced ac-
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Table 2. Classification of the group of diuretics and its specific adverse effects
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tivity of sympatico-adrenal system, secretion of aldo-
sterone and antidiuretic hormone, and thereby low-
ering sodium and water retention. Main representa-
tives are: Captopril, Enalapril, Lisinopril, Fosinopril, 
Quinopril, Ramipril, Perindopril, Moexipril, Tran-
dolapril. The group is very suitable for treatment of 
AH and concomitant diseases likemetabolic syn-
drome, diabetes mellitus (DM), chronic heart failure 
(CHF), renal failure, and ischemic heart disease. The 
most common ADRs are:
 ❖ Dry irritating cough, which occurs in up to 
20% of those taking ACEIsand is thought to 
be due to inhibition of bradykinin breakdown 
(because ACE is identical to kininase II, ACEIs 
may also leadto elevation of bradykinin levels in 
some tissues)
 ❖ Angioedema occurs in less than 1% of patients. 
The reason is the same like previously men-
tioned – accumulation of endogenous brady-
kinin. Drug withdrawal is necessary and some 
patients may require drug treatment and/or 
emergent intubation.
 ❖ Hyperkalemia (should not be administered in 
creatinine clearance below 30 ml/min).
 ❖ Rare side effects – skin rashes, dysgeusia (an al-
teration in or loss of taste), proteinuria (mem-
branous nephropathy), neutropenia (symptoms 
include sore throat and fever) (18).
ACEIs are contraindicated in bilateral renal ar-
tery stenosis and pregnancy, due to renal agenesis 
and fetal death.
AT1 receptor blockers (ARB)
They selectively block angiotensin II - receptor 
type 1 - AT 1. It has been shown that they are as ef-
fective as ACEIs in reduction of blood pressure, the 
degree of proteinuria and slowing the progression of 
renal disease and heart failure. RAAS blockade im-
plemented by both classes of drugs reduces equal-
ly cardiovascular risk (8). Key representatives of the 
ARB are: losartan, valsartan, candesartan, eprosar-
tan, irbesartan, telmisartan. The overall rate of ad-
verse events was comparable, although ACE inhib-
itors were associated with a greater risk for cough. 
The adherence to the therapy with ACE inhibitors 
and ARBs is high (>90%), but the persistence with 
ARDs is better than ACE inhibitors (8). Actually, 
ARBs are the class of antihypertensive drugs with 
the best persistence due to their good tolerance (9). 
The most common ADRs are:
 ❖ Headache, dizziness, fatigue, somnolence, ver-
tigo, anxiety, depression, lightheadedness, 
drowsiness
 ❖ Skin rashes, pruritus
 ❖ Nausea, vomiting, diarrhea, abnormal hepatic 
function, hepatitis
 ❖ Hyperkalemia, hyponatremia
 ❖ Myalgia, paresthesia
 ❖ Leukopenia, agranulocytosis, anemia, 
neutropenia
Like ACEIs, use of ARBs is contraindicated in 
pregnant women because of the association of RAAS 
blockade with increased fetal morbidity and mortali-
ty, particularly with exposure during the second and 
third trimester. 
It is assumed that telmisartan is very suitable 
for the treatment of hypertension with concomitant 
metabolic syndromeon one hand by improving hae-
modynamic response and on the other hand bylow-
ering the risk of developing insulin resistance and 
type 2 diabetes mellitus. The mechanism is not fully 
elucidated, but it is believed that it is associated with 
the modulation of peroxisome proliferator-activated 
receptor (PPAR) (13). 
The newest representative of the RAAS block-
ers is the direct renin inhibitor – aliskiren, which 
binds the proteolytic site of renin, thereby block con-
version of angiotensinogen to angiotensin I, thus re-
ducing the consequent production of angiotensin II. 
The antihypertensive effect is comparable to that of 
ACEIs and ARBs. Aliskiren can cause mild gastroin-
testinal symptoms such as diarrhea observed at high 
doses (600 mg daily), and can also cause cough and 
angioedema, but probably less often than ACE inhib-
itors. The combination with the other RAAS block-
ers is not recommended, since it increases the inci-
dence of adverse effects on renal function.Like oth-
er RAAS inhibitors, aliskiren is not recommended in 
pregnancy.
Calcium channel blockers (CCBs)
They are a heterogeneous group of antihyper-
tensives, blocking the entry of calcium through the 
cell membranes of vascular smooth muscle cells and 
cardiac myocytes. Their hypotensive effect is mainly 
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due to the reduction in peripheral vascular resistance 
(dihydropyridine and non-dihydropyridine) and the 
reduction of heart rate (non-dihydropyridine). The 
main groups of calcium channel blockers and their 
most frequent side effects are given in Table 3.
For the treatment of hypertension retard dosage 
forms of dihydropyridinesare are preferred. Non-re-
tard forms are dangerous in acute forms of coronary 
artery disease. Non-dihydropyridines (verapamil 
and diltiazem) should not be combined with beta-
blockers – risk of severe bradycardia and AV block. 
They are also contraindicated in AF (atrial fibrilla-
tion) + WPW (Wolf-Parkinson-White) syndrome. 
All CCBs can cause gingival hyperplasia, a rare side 
effect that is reversible if detected early but can lead 
to several dental problems if the CCB therapy is not 
suspected as the cause.
Amlodipine is a dihydropyridine CCB from 
the third generation and is the most commonly pre-
scribed agentfrom the group ofCCBs. In recent years 
some new third generation CCBs appeared on the 
market, as lercanidipine, lacidipine and manidipine. 
CCBs may differ, however, in their ability to modu-
late blood flow through the renal afferent and effer-
ent arterioles. In preclinical studies, lercanidipine, a 
third-generation antagonist, dilates both efferent and 
afferent arterioles and reduces intraglomerular pres-
sure and the degree of proteinuria, and thus mimics 
the action of the inhibitors of RAAS. An action on 
both pre- and post-capillary vasodilatation may un-
derlie the reduced clinical incidence of pedal edema, 
the most common side effect ofcalcium antagonists, 
seen with lercanidipine relative to other 1,4-dihydro-
pyridines (19). Addition of lercanidipine to antihy-
pertensive therapy with RAAS blocker leads to fur-
ther benefits for renal function (10,11). Prescription 
of third generation CCBs is associated with improve-
ments in adherence and persistence to antihyper-
tensive therapy. The degree of compliance with the 
prescribed treatment regimen approximates that of 
RAAS blockers. Treatment with lercanidipine over-
comes some of the problems associated with the use 
of other CCBs, such as uneven therapeutic effect, re-
flex sympathetic stimulation, and significantly re-
duces the side effects associated with vasodilation.
Beta-blockers
Beta-blockers are particularly suitable in hyper-
tensive patients with coronary artery disease, some 
arrhythmias, heart failure and glaucoma. The use of 
beta-blockers is questionable and they lose ground in 
some modern guidelines for management of hyper-
tension because of their weak ability to prevent the 
occurrence of strokes and their negative effects on 
the metabolic profile. Not all beta-blockers have the 
same properties and side effects. The main groups of 
beta-blockers and their most frequent side effects are 
given in Table 4.
Class of CCBs Drugs Adverse drug reactions (ADRs)
Dihydropyridine
Nifedipine, Nitrendipine, Felodip-











Contraindicated in sever systolic 
dysfunction
Gingival hyperplasia
Headache, f lushing and edema 
occur less frequently than 
dihydropyridine
Table 3. Classification of the group of calcium channel blockers and its specific adverse effects
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They are contraindicated in obstructive pulmo-
nary disease and AV block II and III degree. The side 
effects are reduced in cardioselective beta blockers. 
More recent data suggest that cardioselective beta 
blockers are safe with moderate or severe chronic ob-
structive pulmonary disease (COPD) (12) and con-
firm the efficacy and safety of selective beta-blockers 





The main representatives are: Prazosin, Doxa-
zosin, and Terazosin. They are used for treatment of 
hypertension and prostatic hypertrophy, and do not 
have adverse metabolic effects. ADRs include:
 ❖ Orthostatic syncope
 ❖ Phenomenon of the first dose - with vertigo, 
dizziness, headache, palpitations.
 ❖ Addiction (prazosin)
 ❖ Swelling, fatigue, weakness
 ❖ Sleepiness, depression
It is not necessary to adjust the dosage of doxa-




The group is used very rarely in modern thera-
py due to the serious side effects. The main represen-
tatives are clonidine, methyldopa and reserpine.
 ❖ Clonidine is suitable for renal failure. Its ADRs 
include dry mouth, depression, lethargy, brady-
cardia, fatigue, orthostatic, rebound-phenome-
non interruption.
 ❖ Methyldopa is preferred for hypertension during 
pregnancy. Its ADRs are hepatotoxicity, auto-
immune reactions, allergic reactions, hemolyt-
ic anemia, leukopenia, and thrombocytopenia.
 ❖ Reserpine is rarely used nowadays. Its ADRs 
are serious and include depression, nightmares, 
suicidal attempts, parkinsonism, drowsiness, 
impaired vision, bradycardia, hyperacidity, na-
sal congestion.
Antagonists of the imidazole receptors
Representatives of this group of antihyperten-
sive drugs are rilmenidin and moxonidin. There was 
no described rebound phenomenon. ADRs include:
 ❖ Nervous system - anxiety, restlessness, insom-
nia, depression, impaired thought processes, 
vertigo, dizziness, drowsiness, fatigue.
 ❖ Gastrointestinal events with nausea, constipa-
tion, diarrhea, stomach pain.
 ❖ Allergic reactions
 ❖ Decreased libido
Direct vasodilators
This group reduces blood pressure by decreas-
ing peripheral vascular resistance. The main repre-
sentatives include hydralazine and minoxidil. They 
are used in refractory hypertension, hypertensive 
crisis, and hypertension in pregnancy, preeclampsia 
and eclampsia. ADRs include:
 ❖ Hydralazine – tachycardia, orthostatic, head-
ache, drug-induced lupus, depression, nausea, 
vomiting, diarrhea.
 ❖ Minoxidil – dizziness, hypotension, electrocar-
diogram changes, tachycardia, sodium
 ❖ and water retention, gynecomastia, hair growth.




Bronchospasm (caution with asthma and 
COPD)
Bradycardia (caution with AV block)
Peripheral vasospasm (especially non-selective 
beta blockers)
Neurological – weakness, fatigue, 
vivid dreams, nightmares, and rarely – 
hallucinations (lipid soluble beta blockers)
Reduced glycose tolerance, mask signs of 
hypoglycemia





Beta blockers with vasodilating 
properties
Carvedilol, Nebivolol
Table 4. Classification of the group of beta-blockers and its specific adverse effects
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Resistant hypertension is considered when a 
treatment strategy involving a change in lifestyle, di-
uretic and antihypertensive drug from two different 
classes, failed to lead to a decrease in blood pressure 
<140/90 mm Hg. For its treatment is recommend-
ed alpha 1 blocker, peripheral vasodilators, min-
eralocorticoid receptor antagonists, centrally act-
ing drugs. In absence of effectiveness of the medi-
cal treatment of resistant hypertension ESH recom-
mends some invasive procedures such as renal sym-
pathetic denervation and baroreceptor stimulation 
performed in specialized centers.
CONCLUSION
The therapy of hypertensive patients should 
be carried out at any age, including patients over 80 
years of age. It has been shown that therapeutic regi-
mens designed to lower blood pressure below 150/80 
mm Hg in the elderly, reduce the risk in total mor-
tality, stroke and cardiovascular events, while there 
are proven benefits and lack of influence to the risk 
for fractures, dementia, depression and quality of life 
(15).
Individual approach, consistency with comor-
bidities, the tolerability profile of prescribed drugs 
and persistence of the patient are the basis for suc-
cessful treatment of hypertension. The commitment 
to antihypertensive therapy reduces by 20% the risk 
of a cardiovascular disease (16). Prescribing many 
drugs with different modes of application, especial-
ly in the presence of another concomitant chronic 
diseases requiring medication, is the reason of dis-
counts of patient’s persistence and termination of the 
prescribed treatment. It has been shown that fixed 
combinations significantly improve commitment to 
treatment and allow better control of blood pressure 
and fewer side effects (17), improving tolerability, and 
is economically more advantageous. Preferred com-
binations in recent years include the RAAS blocker, a 
diuretic and a calcium antagonist. Combining RAAS 
blocker with a diuretic has shown additive effect 
preferably in hypertensive patients with heart failure, 
renal failure, and post-stroke disorders. The combi-
nation of RAAS blocker with a calcium antagonist 
has also an additive effect and is very suitable in hy-
pertensive patients with the metabolic syndrome, a 
high risk of developing diabetes, ischemic heart dis-
ease, peripheral angiopathies, post-stroke, advanced 
age, and isolated systolic hypertension. The combi-
nation of a beta-blocker and a diuretic has an addi-
tive antihypertensive effect, but its use is limited be-
cause of adverse metabolic effects of the two class-
es of drugs, which are reduced in vasodilating beta-
blockers. This combination is used for hypertensive 
patients with heart failure, rhythm pathology, and 
ischemic heart disease.
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